Source Photonics and Credo Semiconductor Demonstrate Single Lambda 100G Connectivity Over 20km of Fiber With Compact TOSA and ROSA Assemblies
ECOC -- Source Photonics and Credo Semiconductor are pleased to announce a single lambda 100Gbits/sec connectivity demonstration over 20km of fiber using a compact TOSA and ROSA capable of 53Gbaud PAM4 operation.
Increasing demand for more bandwidth in Cloud Data Centers is creating the need for more efficient and higher throughput optical transceivers beyond the currently deployed 100G 4x25G WDM technology. These next generation transceivers will need to support higher order modulation techniques such as PAM4 and higher data rate operation at 53Gbaud. Implementations that can be supported with this technology include 400G-DR4/FR4 in addition to 100G-DR/FR/LR.
The demonstration consists of Source Photonics internally packaged TOSA and ROSA sub-assemblies in an optical loopback configuration through 20km of single-mode fiber using a single 100G channel of Credo’s low power PAM4 IC technology. The bit-error-rate (BER) after 20km of fiber remained better than the KP4 FEC requirement and was around 5x10-5. The TOSA is based on Source Photonics’ EML laser technology which provides the necessary bandwidth to achieve a TDECQ value below 2.5dB. The room temperature link budget of 10dB provides considerable margin for the most significant link specifications under development in the industry, allowing production margin for performance variations. These results show that the building blocks necessary to realize 53Gbaud single lambda operation are available and ready to serve the needs of next generation data center deployments.
What this demonstration achieves with one laser and one receiver currently requires four lasers and four receivers – facilitating not only lower cost future 100G but also accelerating the development of 400G products.
“We are continuing to invest in next generation technology, such as Single Lambda 100G, as part of our commitment to providing leading edge solutions for data centers,” said Manish Mehta, EVP, PLM Source Photonics.
“The HyperScale Cloud Providers have spoken and 100G per lambda solutions are a key connectivity priority,” said Rajan Pai, Vice President of System Applications at Credo. “Our unique SerDes architecture allows us to deliver single-lane 100G performance at the lowest power which will enable the volume deployments of 100G and 400G optical modules.”
Source Photonics will be hosting a private demonstration at their booth number 162 at ECOC 2017 to be held in Gothenburg, Sweden from September 18-20, 2017. To schedule an appointment to view the demo, please contact Jasmin Basal at firstname.lastname@example.org.
About Source Photonics
Source Photonics is a leading provider of innovative and reliable optical communications technology that enables communications and connectivity in data centers, metro, and access networks. We invent next-generation solutions to provide customers with enabling technologies to support the rapidly increasing demands of cloud infrastructure, wireless communications, routing, and fiber-to-the-premises worldwide. Source Photonics is headquartered in West Hills, California, with manufacturing facilities, R&D, and sales offices worldwide. For more information about Source Photonics, please visit www.sourcephotonics.com.
About Credo Semiconductor
Credo is a leading provider of high performance, mixed-signal semiconductor solutions for the data center, enterprise networking and high performance computing markets. Credo's advanced Serializer-Deserializer (SerDes) technology delivers the bandwidth scalability and end-to-end signal integrity for next generation platforms requiring single-lane 25G, 50G, and 100G connectivity. The company makes its SerDes available in the form of Intellectual Property (IP) licensing on the most advanced processing nodes and with complementary product families focused on extending reach and multiplexing to higher data rates. Credo is headquartered in Milpitas, California and has offices in Shanghai and Hong Kong. For more information: www.credosemi.com
Jasmin Basal, 818-885-4202
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar16.12.2017 01:13 | Tiedote
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 15:34 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 15:21 | Tiedote
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 14:38 | Tiedote
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 14:00 | Tiedote
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 12:00 | Tiedote
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme